1. Introduction {#sec1}
===============

Adipose tissue functions as a repository for long-term energy storage and as a critical regulator of energy balance, satiety, glucose metabolism, and other physiological processes. White adipose tissue (WAT) stores and releases fatty acids and glycerol in response to the energetic needs of the organism, whereas brown adipose tissue (BAT) produces heat to maintain thermostasis upon cold-exposure. Lipodystrophy is a disease characterized by lack of adipose tissue accompanied by metabolic derangements. The most common form of lipodystrophy is congenital generalized lipodystrophy (CGL), which affects approximately one in ten million individuals and is characterized by a near complete absence of adipose tissue [@bib1]. CGL Type 1 is caused by mutations in 1-acylglycerol-3-phosophate O-acyltransferase 2 (*AGPAT2*) [@bib1], [@bib2] and mice null for *Agpat2* exhibit a complete lipoatrophy [@bib3]. Mutations in *Seipin* cause CGL Type 2, or Berardinelli-Seip congenital lipodystrophy type 2 (*BSCL2*), and mice null for *Bscl2/Seipin*, or with adipose-tissue specific loss, are also lipodystrophic, [@bib4], [@bib5]. Several additional genes have been implicated in CGL and familial partial lipodystrophy, including *Akt2* and a subunit of phosphatidylinositol 3 kinase (*PI3K*) [@bib1], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10]. Hepatomegaly from fatty liver and splenomegaly are common in lipodystrophic patients, with hyperinsulinemia and hypertriglyceridemia often present.

AKT, a Ser/Thr kinase, is activated upon engagement of the insulin receptor and mediates hormonal regulation of many aspects of energy homeostasis in insulin-responsive tissues, including adipose tissue. AKT can also be activated by insulin growth factor 1 (IGF-1) [@bib11], [@bib12], [@bib13]. Three isoforms of AKT have been identified, of which AKT1 and AKT2 account for the majority of AKT in adipocytes [@bib14], [@bib15]. AKT1 is expressed nearly ubiquitously and is critical in the control of growth, while the AKT2 isoform is expressed predominantly in the adult insulin-responsive tissues, including liver, muscle, and adipose. Mice lacking *Akt2* are insulin-resistant [@bib16] but spared from severe metabolic abnormalities due to compensation by Akt1 [@bib17], [@bib18], [@bib19].

In this study, we deleted *Akt1* and *Akt2* selectively in adipocytes of mice, thus interrupting a critical insulin-signaling pathway. We found that loss of these AKT isoforms in adipocytes caused profound lipodystrophy, associated with fatty liver and systemic insulin resistance.

2. Materials and methods {#sec2}
========================

2.1. Adipo-AKT KO mice {#sec2.1}
----------------------

All mice were on a C57/B6 background and were maintained on normal chow diets from Laboratory Rodent Diet, Lab Diet 5001. *Cre*-positive male mice heterozygous for *Akt1* and *Akt2* floxed alleles were bred to females homozygous for *Akt1* and *Akt2* floxed alleles. This breeding scheme generated *Cre*-positive experimental mice homozygous floxed for both genes and *Cre*-negative male mice homozygous floxed for both genes that served as controls. *Cre*-positive males heterozygous for both floxed genes were generated and exhibited a wild type phenotype (data not shown). All mice were born at a Mendelian ratio. All mouse experiments were reviewed and approved by the University of Pennsylvania Institutional Animal Care and Use Committee in accordance with the guidelines of the National Institutes of Health.

2.2. Histopathology {#sec2.2}
-------------------

Organs were harvested for histopathology from 12-week-old mice, fixed in formalin for 24 h, rinsed in 70% ethanol, and stored in 70% ethanol at 4 °C overnight. Sectioning and staining of the liver, spleen, kidney, and pancreas were performed by the Molecular Pathology and Imaging Core at the University of Pennsylvania, supported by NIH grants DK050306, CA098101, and DK049210. Sectioning of the epididymal fat pads was performed by the Pathology Core at the Children\'s Hospital of Philadelphia Research Institute. Staining of the epididymal fat pads was performed in house. Slides were deparaffinized in xylene (3 × 3 min), then rehydrated in an ethanol series of 100% (3 × 3 min), 95% (1 × 3 min), 80% (1 × 3 min), dH2O (1 × 5 min). Slides were stained in hematoxylin for 30 min, rinsed in dH2O, and rinsed in tap water for 5 min. Slides were dipped in acid ethanol 8--12× to destain them, rinsed in tap water (2 × 1 min), and rinsed in dH2O (1 × 2 min). Excess water was removed and slides were stained in eosin for 1 min. Slides were then dehydrated in an ethanol series: 95% (3 × 5 min), 100% (3 × 5 min), and then in xylene (3 × 15 min) before drying and mounting a coverslip.

2.3. F4/80 staining {#sec2.3}
-------------------

Rat anti-mouse F4/80 monoclonal antibody C1:A3-1 from AbD Serotec was used for staining sections from the epididymal fat for macrophage, natural killer cells, and F4/80 positive antigen presenting cell infiltrate. The protocol used was modified from that recommended by the supplier.

2.4. Adipokines {#sec2.4}
---------------

Blood samples were taken from 8 to 12 week old mice between 12 and 2 pm. Adiponectin, leptin, and resistin levels were measured using ELISA kits from Linco by the Radioimmunoassay and Biomarkers Core at the Penn Diabetes Research Center, supported by NIH grant DK19525.

2.5. Liver triglyceride {#sec2.5}
-----------------------

Liver triglycerides were measured by weighing 100 mg liver and lysing in 400 uL cell lysis buffer (50 mM Tris, pH 7.4, 140 mM NaCl, 0.1% Triton-X) (250 mg/mL homogenate). Samples were diluted 10 fold and incubated in 1% deoxycholate at a 1:1 ratio for 10 min, then incubated for 10 min in Thermo-Scientific Infinity Triglyceride reagent. All incubations were performed at 37 °C. The Stanbio triglyceride standard was used. Samples were read on a Tecan plate reader at 500 nm.

2.6. Glucose homeostasis {#sec2.6}
------------------------

For glucose tolerance tests, 8--12 week old male mice were fasted for 16--18 h overnight and injected with 1 g/kg glucose intraperitoneally. Blood samples were taken from the tail in Sarstedt microvette lithium heparin tubes (Ref 16.433.100) at time 0 for fasting insulin measurements and 15 min post injection. Blood glucose levels were taken from the tail on a OneTouch Ultra glucometer at fasting, and post-injection at 15, 30, 60, and 120 min.

For the meal challenges, 8--12 week old male mice were fasted for 16--18 h overnight and then refed normal chow for 2 h.

Crystal Chem Ultra-sensitive Mouse Insulin ELISA kits were used for all insulin measurements. WAKO NEFA assay kits were used for all NEFA measurements.

3. Results {#sec3}
==========

3.1. Loss of AKT1 and AKT2 in adipocytes causes lipodystrophy {#sec3.1}
-------------------------------------------------------------

To determine the role of AKT in regulating adipocyte function and survival, we generated mice lacking both *Akt1* and *Akt2* using the *AdipoQ-Cre* driver [@bib20]. Adipo-AKT knockout (KO) mice were severely lipodystrophic at 8--12 weeks of age such that all subcutaneous and cutaneous fat depots, including interscapular brown adipose tissue, were completely absent ([Figure 1](#fig1){ref-type="fig"}A). The epididymal WAT was about 10× smaller (as a percentage of body weight) in Adipo-AKT KO mice as compared to control mice ([Figure 1](#fig1){ref-type="fig"}B). Hematoxylin and Eosin staining of tissue sections showed that the residual epididymal WAT (eWAT) in KO mice contained a modest number of enlarged adipocytes ([Figure 1](#fig1){ref-type="fig"}C). The KO eWAT also displayed increased infiltration of F4/80+ macrophages ([Figure 1](#fig1){ref-type="fig"}D). The levels of important adipokines, such as leptin, adiponectin, and resistin, were dramatically decreased in Adipo-AKT KO mice relative to controls ([Figure 1](#fig1){ref-type="fig"}E). The body weight of Adipo-AKT KO mice was increased about 15% by 5 weeks of age, with controls weighing ∼17.3 g and Adipo-AKT KO mice weighing ∼20.5 g ([Figure 1](#fig1){ref-type="fig"}F). This increase in body weight was maintained at 9 weeks of age with control mice weighing ∼21.8 g and Adipo-AKT KO mice weighing ∼26.0 g ([Figure 1](#fig1){ref-type="fig"}F). These results show that AKT is required for the maintenance of adipose tissues.

3.2. Hepatomegaly {#sec3.2}
-----------------

Adipo-AKT KO mice had livers weighing 2.7 times that of control animals when normalized for body weight at 8--12 weeks of age. Livers in Adipo-AKT mice constituted 13% of body weight, and were 3.5 g on average, as compared to 4.9% of body weight and about 1 g in controls ([Figure 2](#fig2){ref-type="fig"}A,B). The greater size of KO livers was associated with a large increase in liver triglyceride levels. Control mice had an average of 9.2 mg triglyceride/g of liver whereas Adipo-AKT KO livers had 169.1 mg triglyceride/g of liver ([Figure 2](#fig2){ref-type="fig"}C). Histopathological analysis of livers from Adipo-AKT KO mice revealed a disorganized morphology with an increase in both the number and size of lipid droplets ([Figure 2](#fig2){ref-type="fig"}D).

3.3. Organomegaly {#sec3.3}
-----------------

In addition to hepatomegaly, the Adipo-AKT KO mice displayed enlarged pancreases and kidneys ([Figure 3](#fig3){ref-type="fig"}A). On the other hand, Adipo-AKT KO mice did not exhibit splenomegaly, which is often associated with lipodystrophy [@bib1], [@bib21], [@bib22], [@bib23] ([Figure 3](#fig3){ref-type="fig"}A). Histopathology of both the spleen and kidney revealed no obvious abnormalities ([Figure 3](#fig3){ref-type="fig"}B,C). In contrast, the pancreases of Adipo-AKT KO mice had enlarged islets ([Figure 3](#fig3){ref-type="fig"}D).

3.4. Glucose homeostasis {#sec3.4}
------------------------

We next assessed glucose homeostasis in control and Adipo-AKT KO mice. Adipo-AKT KO mice had glucose tolerance comparable to control mice at 8--12 weeks of age ([Figure 4](#fig4){ref-type="fig"}A). However, while control mice had fasting insulin levels of ∼0.5 ng/mL, levels in the KO mice were appreciably higher at 2.5 ng/mL, indicative of significant insulin resistance ([Figure 4](#fig4){ref-type="fig"}B). To further investigate the ability of Adipo-AKT KO mice to regulate blood glucose in the face of insulin resistance, we fasted mice overnight and challenged them with a meal of normal chow. Two hours after refeeding, blood glucose levels were significantly greater in the Adipo-AKT KO mice than the controls ([Figure 4](#fig4){ref-type="fig"}C). Consistent with the results from GTT, the insulin levels were elevated in fasted Adipo-AKT KO and increased even further following feeding ([Figure 4](#fig4){ref-type="fig"}D).

Plasma non-esterified fatty acids (NEFA) levels were also measured during fasting and after a 2 h feeding challenge on normal chow. Adipo-AKT KO mice had low basal NEFA levels of 0.7 mmol/L compared to control mice that had fasting NEFA of 1.6 mmol/L. Postprandially, NEFA levels in control mice are suppressed to 0.68 mmol/L while in Adipo-AKT KO mice NEFA levels were not changed ([Figure 4](#fig4){ref-type="fig"}E).

4. Discussion {#sec4}
=============

Our findings indicate that AKT1 and/or AKT2 are required for adipose maintenance *in vivo*. The severity of insulin resistance in the Adipo-AKT KO mice and their inability to regulate blood glucose postprandially follows the pattern observed in human patients with lipodystrophy, many of whom develop frank diabetes following puberty [@bib1], [@bib2], [@bib24]. Multiple mouse models of lipodystrophy have been developed that recapitulate characteristics of human lipodystrophy. Mutations in *AGPAT-2* and *BSCL-2*/seipin account for most human lipodystrophy patients, CGL Type I and CGL Type II, respectively [@bib2], [@bib6], and mice null for these genes have lipodystrophic and insulin resistant phenotypes [@bib3], [@bib4]. Several other genes have been manipulated in mice resulting in lipodystrophy, notably the AZIP/F-1 dominant negative mouse, which interferes with adipocyte development, the lamin A (*LMNA*) dominant negative mouse that inhibits adipose renewal, and adipocyte-specific loss of peroxisome proliferator-activated receptor gamma (PPARγ), a transcription factor required for adipocyte differentiation and maintenance [@bib10], [@bib25], [@bib26], [@bib27].

Studies performed *in vitro* established that AKT signaling is necessary for adipogenesis in cultured cells [@bib19], [@bib28], [@bib29], [@bib30], [@bib31]. AKT1 is required for adipogenesis in mouse embryo fibroblasts (MEFs) and 3T3L1 preadipocytes, while AKT2 is dispensable [@bib28], [@bib29], [@bib30]. Mechanistically, AKT functions in precursor cells to suppress Foxo1 activity [@bib28], [@bib31]. The isoform specificity *in vitro* are in conflict with *in vivo* data from *Akt1* null mice, that have an overall smaller body size but do not exhibit a lipodystrophic phenotype [@bib32], [@bib33]. This suggests that either non-autonomous factors influence adipogenesis, or that AKT2 can support adipogenesis in the whole animal. Additionally, *Akt2* null mice have been suggested to develop an age-dependent lipodystrophy [@bib34]. Our data expand on these studies and document a critical role for AKT signaling in maintaining mature adipocytes.

The *AdipoQ-Cre* transgene is thought to be mainly expressed in mature adipocytes [@bib20], [@bib35], [@bib36], [@bib37]. Mullican et al. (2013) and Lee et al. (2013) showed that recombination does not occur in the stromal vascular fraction of adipose tissue depots [@bib36], [@bib37]. Consistent with this, Berry and Rodeheffer (2013) found that highly purified adipogenic precursor cells in WAT do not express *AdipoQ-Cre* [@bib35]. Interestingly, a recent study shows that adiponectin is expressed at the embryonic stage in adipocyte precursors of inguinal WAT but not in adult preadipocytes [@bib38]. It is unclear if *AdipoQ-Cre* is also expressed at sufficient levels in this population to induce efficient recombination. Moreover, it is not known if adipose precursors of other depots, such as the epididymal WAT similarly express adiponectin during embryogenesis. The *AdipoQ-Cre* mediated deletion of AKT in our model may thus reflect defects in adipocyte differentiation and maintenance, depending on the depot.

There are three AKT isoforms, AKT1-3, that function in the insulin signaling pathway. Each of these isoforms is expressed in adipocytes, but AKT2 is the most abundant isoform [@bib14], [@bib15]. Mice null for *Akt1* and *Akt2* are born with dwarfism, are not viable, and MEFs derived from these animals are unable to undergo adipogenesis [@bib19]. AKT3 is expressed in differentiated adipocytes [@bib39], but it is clearly not sufficient to preserve adipocyte insulin/IGF signaling in the absence of both AKT1 and AKT2.

The insulin and insulin-like growth factor 1 (IGF-1) pathways converge on the insulin receptor substrate and phosphoinositide-3-kinase (PI3K), upstream of AKT [@bib40], [@bib41], [@bib42]. Loss of AKT1 and AKT2 in adipocytes likely ablates both insulin signaling and IGF-1 signaling, potentially contributing to the severity of the lipodystrophy. Concurrent deletion of the insulin receptor and insulin growth factor 1 receptor (IGF1R) using *aP2-Cre* causes lipodystrophy with a greater reduction in BAT size than WAT when compared to the IR knockout alone, suggesting that IGF1R signaling has a more important role in BAT than in WAT [@bib43], [@bib44]. Interpretation of these data is confounded by the use of the *aP2-Cre*. While the requirement for IR and IGF1R signaling may differ between depots, all depots depend on AKT-function.

The Adipo-AKT KO mice display profound hepatomegaly and a small but significant renomegaly along with increased pancreas weight ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}D). This organomegaly is also observed in some human lipodystrophic patients, with hepatomegaly often being most prominent [@bib1], [@bib21], [@bib22], [@bib23]. Hyperinsulinemia potentially contributes to the increased body size and organomegaly of Adipo-AKT KO mice through enhanced IR/IGFR-1 signaling. Another possible contributor to organomegaly is increased food intake as a result of reduced circulating levels of leptin ([Figure 1](#fig1){ref-type="fig"}E), a critical regulator of energy homeostasis [@bib17], [@bib45], [@bib46], [@bib47], [@bib48]. Increased food intake and decreased movement were observed in the AGPAT −/− lipodystrophy model and normalized with leptin supplementation [@bib46]. Though not measured in this study, it is likely the Adipo-AKT KO mice would exhibit a similar phenotype.

Surprisingly, Adipo-AKT KO mice had low plasma NEFA levels, a phenomenon also observed in some human lipodystrophic patients [@bib9]. These patients exhibit post-prandial plasma NEFA levels unchanged from their fasting levels [@bib9]. Similarly, the Adipo-AKT KO mice had refed NEFA levels that were not significantly differently from either their fasted levels or the fed levels in control mice. In many mouse models of lipodystrophy, there are high fed plasma NEFA levels [@bib25], [@bib26], [@bib27]. Interestingly, genetic background influences lipid profiles in lipodystrophic AZIP/F-1 mice [@bib49]. On a FVB background AZIP/F-1 mice have abnormally high NEFA levels, whereas NEFA levels are similar between control and AZIP/F-1 mice on a C57/B6 background [@bib49]. Similarly, *Agpat2* and *Bscl-2/seipin* null mice, both in the C57/B6 background, have normal NEFA levels [@bib3], [@bib4]. These mice, and the C57/B6 AZIP/F-1 mice, have significantly decreased fasting NEFA levels [@bib25], similar to the Adipo-AKT KO mice. By contrast, adipocyte-specific deletion of *Bscl-2/seipin* results in a milder lipodystrophy and these mice do not have reduced fasting NEFA levels [@bib5]. Given the severity of lipodystrophy in the Adipo-AKT KO mice, it follows that they have no available adipose stores to undergo lipolysis and release fatty acids in response to a fasting state.

5. Conclusions {#sec5}
==============

Our mouse model recapitulates many of the features observed in a familial lipodystrophy syndrome caused by loss of function mutations in *Akt1* and *Akt2*, including insulin resistance and hepatomegaly [@bib7]. Our study also demonstrates that AKT signaling, likely acting downstream of the insulin and IGF-1 receptors, is critically required for proper adipose expansion and/or maintenance.
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![Adipo-AKT KO mice are lipodystrophic. A. Control and Adipo-AKT KO mice lack subscapular white and brown fat depots (black box). B. Epididymal fat pads and fat pad weights from control and Adipo-AKT KO mice (control n = 4, Adipo-AKT KO n = 6). C. H&E staining of the epididymal fat pad depots. D. F4/80 staining of the epididymal fat pad depots. E. Circulating canonical adipokines leptin, adiponectin, and resistin (control n = 9, Adipo-AKT KO n = 8). F. Growth curve of control and Adipo-AKT KO mice (control n = 10, Adipo-AKT KO n = 12). All data are presented as mean ± s.e.m. (\*, p \< .05; \*\*\*\*, p \< .0001).](gr1){#fig1}

![Adipo-AKT KO mice have hepatomegaly. A. Adipo-AKT KO mice have enlarged and pale livers. B. Liver weights in control and Adipo-AKT KO mice. (control n = 4, Adipo-AKT KO n = 6). C. Stored liver triglycerides in liver of control and Adipo-AKT KO mice (n = 6). D. H&E staining of the liver from control and Adipo-AKT KO mice (20×). All data are presented as mean ± s.e.m. (\*, p \< .05; \*\*\*\*, p \< .0001).](gr2){#fig2}

![Adipo-AKT KO mice have enlarged pancreases and renomegaly. A. Organ weights of control and Adipo-AKT KO mice (control n = 4, Adipo-AKT KO n = 6). B. H&E staining of the spleen (10×). C. H&E staining of the kidney (10×). D. H&E staining of the pancreas (10×). All data are presented as mean ± s.e.m. (\*, p \< .05).](gr3){#fig3}

![Adipo-AKT KO mice are insulin-resistant. A. Glucose tolerance tests were performed after an overnight fast, time 0, and 1 g/kg glucose was injected intraperitoneally with glucose measurements taken at 0, 15, 30, 60, and 120 min (control n = 9, Adipo-AKT KO n = 19). B. Serum insulin levels were collected at time 0 and 15 min after glucose injection. (control n = 8, Adipo-AKT KO n = 14). C. Blood glucose levels following an overnight fast and 2 h meal challenge in control and Adipo-AKT KO mice (control n = 8, Adipo-AKT KO n = 11). D. Serum insulin levels following an overnight fast and 2 h meal challenge in control and Adipo-AKT KO mice (control n = 5, Adipo-AKT KO n = 11). E. Serum non-esterified fatty acids after an overnight fast and 2 h meal challenge (control n = 4, Adipo-AKT KO n = 6). All data are presented as mean +/− s.e.m. (\*, p \< .05; \*\*\*\*, p \< .0001).](gr4){#fig4}

[^1]: Present address: CVMED, Pfizer Inc., Cambridge, MA, USA.
